Lipid CME
LECTURECME

Advancing Science in Residual Cardiovascular Risk: Will New Cardiovascular Outcomes Trials Bring a Paradigm Shift in Patient Care?

Author(s)/Faculty: Christie M. Ballantyne, MD; Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC; Michael Miller, MD, FACC, FAHA
Release Date: 1/4/2019Expiration Date: 1/3/2020
Credit Type: CMENumber of Credits: 1.25
Content Type: LectureProvider:
Despite therapeutic advances, cardiovascular disease (CVD) continues to be the leading cause of preventable death in the United States. Because hyperlipidemia is a major risk factor for CVD, the treatment of elevated cholesterol (particularly low-density lipoprotein cholesterol [LDL-C]) has been a major focus of preventative therapy. Of note, however, high triglyceride (TG) levels are independently associated with an increased risk of CVD after adjustment for LDL-C levels. Patients presenting with hypertriglyceridemia may also have multiple CVD risk factors. There is growing recognition of residual risk and adverse cardiovascular events occurring in patients with hypertriglyceridemia. Notably, the risk conferred by elevated TGs occurs independent of LDL-C levels. The addition of omega-3 fatty acids to statin therapy has been proven to help reduce the risk of adverse cardiovascular events and thereby optimize outcomes. Yet, there are differences in omega–3-based agents, with new clinical data that promise to change the way patients are treated. This CME activity will feature clinical expert perspectives on new findings to improve long-term patient outcomes in those with residual risk.